Factors Associated with Corticosteroid Adherence in Sarcoidosis.

Autor: Judson MA; Department of Medicine, Albany Medical Center, Albany, NY, USA. judsonm@amc.edu.; Division of Pulmonary and Critical Care Medicine, Albany Medical College, MC-91, Albany, NY, 12208, USA. judsonm@amc.edu., Ouedraogo WO; Department of Epidemiology and Biostatistics, College of Public Health, Temple University, Philadelphia, PA, USA., Fish KM; Department of Medicine, Albany Medical Center, Albany, NY, USA., DeLuca R; Department of Medicine, Albany Medical Center, Albany, NY, USA., VanCavage R; Department of Medicine, Albany Medical Center, Albany, NY, USA., Sirigaddi K; Memorial Health- Harrington Hospital, Southbridge, MA, USA., Yucel R; Department of Epidemiology and Biostatistics, College of Public Health, Temple University, Philadelphia, PA, USA.
Jazyk: angličtina
Zdroj: Lung [Lung] 2024 Sep 23. Date of Electronic Publication: 2024 Sep 23.
DOI: 10.1007/s00408-024-00746-7
Abstrakt: Purpose: We measured corticosteroid medication adherence (CMA) in sarcoidosis patients and analyzed if demographic and clinical factors, beliefs about medications, corticosteroid side-effects, psychosocial status, and the doctor-patient relationship were associated with corticosteroid adherence.
Methods: Sarcoidosis patients receiving corticosteroids were eligible to participate. CMA was measured using the Medication Adherence Response Scale-10 (MARS-10), a validated patient reported outcome measure (PRO). Data collection included patient demographics and clinical variables to assess their sarcoidosis phenotype. The patients were administered additional PROs concerning their psychosocial status, beliefs about medication use, corticosteroid side-effects and the strength of their doctor-patient relationship.
Results: 132 patients were enrolled. Their mean prednisone dose was 9.9 ± 7.5 mg/day. 75% (99/132) were adherent with corticosteroids (MARS-10 ≥ 6) and 25% (33/132) were nonadherent (MARS-10 < 6). All demographic features, education level, and annual family income were not associated with CMA. Most clinical variables including spirometry, use of additional sarcoidosis drugs, number of organs involved with sarcoidosis were not associated with CMA. Almost all PROs including a better attitude toward medication use, less psychological issues, less corticosteroid side-effects, and a stronger doctor-patient relationship were associated with better CMA. A multi-logistic regression found that patient-doctor communication and the patient's intrinsic beliefs about the use of medications remained associated with CMA.
Conclusion: We found no significant relationship between demographic or socioeconomic factors and CMA. Few clinical factors were associated with CMA. In a univariate analysis, CMA was associated with physician-doctor communication, beliefs about medication use, psychological/emotional issues, and corticosteroid side-effects. Only the first two of these factors remained associated with CMA in a multi-logistic analysis. These data suggest that CMA is heavily influenced by sarcoidosis patient beliefs about medications, and less so by patient demographics.
(© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: